topicMagnesium Glycinate Sleep Onset Randomized Trial
claimTemporomandibular disorders (TMDs) are among the most common causes of chronic orofacial pain, with myalgia of the masticatory muscles being a major.Patients frequently present with persistent aching pain, muscle tenderness, and restricted jaw function, all of which significantly impair quality of life.While existing treatments are mainly symptomatic,emerging evidence suggests a role for electrolyte modulation.
evidence level1
citationPatil Shankargouda (2026)
sourceThe Role of Electrolytes in Muscle Pain Syndromes: A Systematic Review and Meta-Analysis With Implications for Temporomandibular Disorder
topicMagnesium Glycinate Sleep Onset Randomized Trial
claimNotably, a recent randomized controlled trial demonstrated that local magnesium sulphate injection into the masseter muscle significantly reduced pain intensity and improved function in TMD myalgia, providing a direct clinical link between electrolyte biology and orofacial pain.This observation highlights the potential for broader exploration of electrolyte-based interventions in TMD.
evidence level1
citationPatil Shankargouda (2026)
sourceThe Role of Electrolytes in Muscle Pain Syndromes: A Systematic Review and Meta-Analysis With Implications for Temporomandibular Disorder
topicMagnesium Glycinate Sleep Onset Randomized Trial
claimMuscle cramps – whether idiopathic nocturnal, pregnancy-associated, or exercise-induced – arise from abnormal neuromuscular excitability,impaired ion-channel regulation,and nociceptor sensitization.These same processes are also implicated in TMD myalgia,suggesting that insights from cramp interventions may inform novel strategies for managing orofacial muscle pain.
evidence level1
citationPatil Shankargouda (2026)
sourceThe Role of Electrolytes in Muscle Pain Syndromes: A Systematic Review and Meta-Analysis With Implications for Temporomandibular Disorder
topicMagnesium Glycinate Sleep Onset Randomized Trial
claimResults: Among participants with ≥2.5 years of follow-up, mean MoCA increased from 21.7 to 22.5, and 73% (16/22) demonstrated improvement (≥2-point increase) or stabilization (-1 to +1 points).
evidence level4
citationKogan M (2026)
sourceThe Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series.
topicMagnesium Glycinate Sleep Onset Randomized Trial
claimBackground: Alzheimer's disease (AD) and related dementias remain major public health challenges with limited treatment options.
evidence level4
citationKogan M (2026)
sourceThe Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series.
topicMagnesium Glycinate Sleep Onset Randomized Trial
claimPersonalized, multimodal integrative approaches have emerged as potential strategies for patients with mild cognitive impairment (MCI) and early-stage AD.
evidence level4
citationKogan M (2026)
sourceThe Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series.